On the other hand, the efficacy of a combined treatment between trametinib or selumetinib and cytotoxic agents in NSCLC cells represented a strong rationale to use this drug combination as a potent strategy to improve treatment response in NSCLC patients with KRAS mutations (Figure 3) [77]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.